NCT04509323 is a Phase 4 clinical trial of Huperzine A for Injection in Neurosensory Disorder, sponsored by Jiangsu Famous Medical Technology Co., Ltd..

Who is sponsoring NCT04509323?

NCT04509323 is sponsored by Jiangsu Famous Medical Technology Co., Ltd..

What drugs are being tested in NCT04509323?

Interventions in NCT04509323: Huperzine A for Injection.

What condition does NCT04509323 study?

NCT04509323 studies Neurosensory Disorder.

Is NCT04509323 still recruiting?

NCT04509323 is currently status unknown. Last updated 12 August 2020.

Last reviewed 2020-08-12 · How we verify

NCT04509323

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

Status unknown Phase 4 Last updated 12 August 2020

What this trial tests

Phase 4 trial testing Huperzine A for Injection in Neurosensory Disorder in 20 participants. Status unknown.

Timeline

3 August 2020

Primary endpoint
28 February 2021

28 May 2021

Quick facts

Lead sponsor	Jiangsu Famous Medical Technology Co., Ltd.
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	3 August 2020
Primary completion	28 February 2021
Estimated completion	28 May 2021
Sites	1 location across China

Drugs / interventions tested

Huperzine A for Injection — full drug profile →

Conditions studied

Neurosensory Disorder — all drugs for Neurosensory Disorder →

Sponsor

Jiangsu Famous Medical Technology Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Neurosensory Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage； 2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Jiangsu Famous Medical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07129499 — Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas · NA · not yet recruiting
NCT07123116 — Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas · NA · not yet recruiting
NCT06613373 — An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Bre · Phase 4 · not yet recruiting
NCT06537674 — Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive · not yet recruiting
NCT06136026 — Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04509323 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Famous Medical Technology Co., Ltd.
Last refreshed: 12 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509323.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing